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Figure 1 Pedigree of family 232. Blackened circles indicate affected women; blackened squares indicate affected men; and a diagonal
slash indicates that the patient is deceased. Individual identification numbers appear directly below the symbols. Breast cancer is indicated with
age at diagnosis (“dx”); bilateral breast cancer is indicated (“bil”) with ages at diagnoses; “PSU” indicates primary site not known; and “TAH-
BSO” indicates a complete abdominal hysterectomy, including bilateral oophorectomy. The plus sign () indicates the presence of the BRCA1
G2508T mutation and the BRCA2 3295insA mutation, in the proband tested. The minus sign () indicates the absence of these two mutations
in BRCA1 and BRCA2.
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A Breast Cancer Patient of Scottish Descent with
Germ-Line Mutations in BRCA1 and BRCA2
To the Editor:
Ramus et al. (1997) previously described an Ashkenazi
Jewish patient found to have germ-linemutations in both
breast and ovarian cancer–susceptibility genes, BRCA1
and BRCA2. We report the first such example for the
non-Jewish Caucasian population. The patient, who is
indicated by an arrow in pedigree 232 (fig. 1), was of
Scottish origin. She was diagnosed with breast cancer
(grade 2 adenocarcinoma) at age 35 years. Simultaneous
screening by protein truncation test of both BRCA1
(exon 11) and BRCA2 (exon 11) detected truncating
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mutations. Direct sequencing revealed BRCA1 G2508T
as a nonsense mutation resulting in Glurstop codon and
BRCA2 3295insA as an in-frame stop codon at position
1025. Mutation results were confirmed at a separate
BRCA1 and BRCA2 testing facility in Toronto. These
are novel mutations not previously reported in the Breast
Cancer Information Core database.
This patient had a maternal and paternal history of
breast cancer. The maternal side contained cases of post-
menopausal breast cancer: her mother (patient 6) was
diagnosed with bilateral breast cancer at ages 70 and
75 years, and her aunt (patient 5) was diagnosed at ages
68 and 72 years; her grandmother (patient 2) was di-
agnosed with breast cancer at age 72 years. The paternal
side contained cases of premenopausal breast cancer: a
cousin once removed (patient 35) was diagnosed with
breast cancer at age 33 years, her grandmother (patient
20) was diagnosed at age 75 years, and a distant cousin
(patient 59) was diagnosed at age 35 years. Interestingly,
her mother did not have either mutation, suggesting that
both BRCA1 and BRCA2 germ-line mutations origi-
nated from the father of the proband. This is consistent
with the ages at onset of the women on the paternal
side, indicating the presence of at least one of these mu-
tations in the women diagnosed with premenopausal
breast cancer. To date, no other family members are
available for testing. For counseling of individuals iden-
tified as double heterozygotes for mutations in BRCA1
and BRCA2, the risk of transmitting a breast can-
cer–susceptibility gene(s) to any offspring is 3/4.
The frequency of BRCA1 and BRCA2 mutations in
the United Kingdom and Canada has been estimated at
1/850–1/500 individuals (Easton 1993; Ford et al.
1995); therefore, the likelihood of finding a double het-
erozygote in this population is between 1/700,000 and
1/250,000. It is estimated that, for individuals of Ash-
kenazi Jewish descent, the likelihood of being a carrier
for one of three common BRCA1 or BRCA2 mutations
is x1/50 (Roa 1996; Tonin et al. 1996); therefore, the
likelihood of finding a double or compound heterozy-
gote is ∼1/2,500 for Ashkenazi Jewish families unse-
lected for cancer.
This individual is the first example to date of a double
heterozygote for the high-penetrance breast can-
cer–susceptibility genes, BRCA1 and BRCA2, outside of
the Ashkenazi Jewish population (Ramus et al. 1997).
This finding is predictably rare, with a maximum fre-
quency of 1/250,000. Our patient was diagnosed with
early-onset breast cancer at age 35 years, an age typical
of other BRCA1/BRCA2–associated breast cancers. Her
case does not suggest a more severe presentation or
younger age at diagnosis for women found to harbor
germ-line mutations in both genes. We cannot generalize
that complete screening of BRCA1 and BRCA2 in fam-
ilies with a previously identified mutation in either gene
is necessary until other double heterozygotes are iden-
tified. However, if the family mutation is not found in
women diagnosed with early-onset breast cancer or
ovarian cancer, there is a basis for comprehensive screen-
ing of both genes.
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Evidence of Founder Mutations in Finnish BRCA1 and
BRCA2 Families
To the Editor:
Approximately 4%–10% of breast and ovarian cancer
is thought to be inherited (Newman et al. 1988). Most
hereditary ovarian cancer cases and a significant portion
